In a report released on September 6, Brandon Couillard from Wells Fargo maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – ...

Maravai LifeSciences (NASDAQ:MRVI) may be worth $15 to $20 a share in a potential takeover based on precedent transactions, according to an RBC analyst, after a report that Repligen (RGEN) has a ...

Stay informed and make strategic decisions with our Ratings Table. Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies ...

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled ...

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support ...

Maravai LifeSciences, a leader in life sciences, drives innovation by providing critical products and services across nucleic acid synthesis, biologics safety testing and more. Its companies ...

The average one-year price target for Maravai LifeSciences Holdings (NasdaqGS:MRVI) has been revised to 9.98 / share. This is ...

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support ...

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases.